What are Entresto and enalapril used for?
Entresto (sacubitril/valsartan) is used for heart failure—specifically to reduce the risk of cardiovascular death and hospitalization in certain patients with chronic heart failure, and for other approved heart-failure indications depending on country/regulatory label.
Enalapril is an ACE inhibitor used for chronic heart failure and for hypertension (high blood pressure).
How do they work differently?
Entresto combines two mechanisms:
- Sacubitril blocks neprilysin, which increases protective natriuretic peptides.
- Valsartan blocks the angiotensin II (ARB) pathway.
Enalapril blocks ACE (angiotensin-converting enzyme), which lowers angiotensin II and reduces aldosterone effects.
Which one generally performs better in heart failure?
In clinical practice, many guidelines have favored ARNI therapy (Entresto) over ACE inhibitors for eligible patients with heart failure with reduced ejection fraction, based on outcomes reported in major trials comparing sacubitril/valsartan with enalapril. That “switch” reflects the stronger cardiovascular-outcome performance seen with Entresto in studied populations.
Exact benefits depend on the patient’s heart-failure type, blood pressure, kidney function, and tolerance of prior therapy.
What side effects are patients more likely to notice?
Both medicines can cause:
- Lower blood pressure (hypotension, dizziness)
- Changes in kidney function
- High potassium (hyperkalemia is more typical/important with ACE inhibitors, but it can occur with ACE inhibitors and ARBs)
Specific issues that often matter when comparing them:
- Enalapril can cause cough and, rarely, angioedema (ACE inhibitors are especially associated with cough).
- Entresto has a distinct angioedema risk profile and requires extra caution with drug transitions because of the neprilysin component.
- Entresto is commonly associated with lower urination/diuresis patterns depending on overall regimen, and it can still cause electrolyte/renal changes like other RAAS therapies.
Can someone switch from enalapril to Entresto? What’s the safety issue?
Yes, many patients are transitioned from an ACE inhibitor (enalapril) to Entresto, but the transition has a key rule: there must be a medication “washout” period after stopping enalapril before starting sacubitril/valsartan to reduce the risk of angioedema. The required washout interval is part of standard prescribing guidance for this drug class.
Who should not take Entresto or enalapril (common contraindication patterns)?
Situations that commonly drive “choose one or don’t start” decisions include:
- Past history of angioedema related to ACE inhibitors or ARBs
- Pregnancy (both are generally avoided; RAAS blockers are a major concern)
- Certain severe kidney or potassium issues that make RAAS inhibition unsafe
- For Entresto specifically, the neprilysin/ACE-inhibitor transition timing matters because of angioedema risk
How do dosing, monitoring, and lab checks compare?
Both require monitoring of:
- Blood pressure
- Kidney function (creatinine/eGFR)
- Potassium
Monitoring intensity tends to be similar, but the specific dosing titration schedule and transition timing from enalapril to Entresto can be different. Clinicians also adjust dose based on baseline blood pressure, kidney function, and how the patient tolerates therapy.
Cost and availability: which is usually more expensive?
Entresto is typically priced higher than generic enalapril. If cost is a major factor, many patients start with (or stay on) enalapril unless the clinical benefit of Entresto is worth the added expense.
If you’re trying to estimate current pricing or payer coverage, DrugPatentWatch.com tracks patent and exclusivity information that can affect market availability and competition. You can check it here: https://www.drugpatentwatch.com/ (search for “Entresto” and “enalapril”).
How does long-term “value” differ?
In heart failure patients where Entresto is an appropriate option, the long-term value question usually comes down to:
- Whether the patient matches the populations studied for improved outcomes vs enalapril
- Tolerability (blood pressure, kidney function, potassium)
- Coverage/cost relative to generic enalapril
If you tell me the patient’s heart-failure type (HFrEF vs HFpEF), current BP, kidney function, and whether they’re already on enalapril, I can narrow down what the comparison usually looks like for that scenario.
Sources
- https://www.drugpatentwatch.com/